Automated And Rapid Microbiological Tests: Market Research Report

Date: January 5, 2014
Pages: 371
Price:
US$ 4,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A6B2F59672BEN
Leaflet:

Download PDF Leaflet

Automated And Rapid Microbiological Tests: Market Research Report
This report analyzes the worldwide markets for Automated And Rapid Microbiological Tests in US$ Thousands by the following End-Use Segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, & Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 103 companies including many key and niche players such as -
  • Abbott Laboratories
  • Alere Inc.
  • Becton Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Clinical Applications
Automated Identification and Susceptibility Systems
Automated Blood Culture Systems
Automated Tuberculosis Systems
Streptococcal Infection Rapid Tests
GC/Chlamydia Rapid Tests
Other Automated & Rapid Microbiological Tests
Non-Clinical Applications

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

Global Invitro-Diagnostics Market

Table 1. Global In Vitro Diagnostics (IVD) Market by Geographic Region (2013): Percentage Share Breakdown of Revenues for the United States, Europe, and Rest of World (includes corresponding Graph/Chart)
Table 2. Global In-Vitro Diagnostics Market by Sector (2013): Percentage Breakdown of Revenues for Hospital & Commercial Laboratories, Decentralized & Patient Self-Testing, (includes corresponding Graph/Chart)
Table 3. Global In-Vitro Diagnostics Market by Segment (2013): Percentage Breakdown of Value Sales for Hematology, Hemostasis, Immunochemistry, Microbiology, Molecular Diagnostics, Point-of-Care Diagnostics, Self-Monitoring Blood Glucose, and Tissue Diagnostics (includes corresponding Graph/Chart)
Table 4. Global In Vitro Diagnostics Market by Leading Player (2013): Percentage Share Breakdown of Revenues for Abbott, Biomerieux, Danaher, J&J, Roche, Siemens and Others (includes corresponding Graph/Chart)

Automated and Rapid Microbiological Tests Revolutionize Microbiological Testing
Evolutionary Battle against Microbes Drives Market Future
Automated Microbiological Tests: A Pesky Gray Area in the Clinical Diagnostics Market
Instant Detection of Pathogens – A New Epoch in the Fight for Survival
Traditional Rapid Microbiological Tests Make Way for New, Probe Tests
Emerging Markets Provide Tremendous Growth Opportunities
Clinical Applications

Table 5. Global Automated and Rapid Microbiological Tests Market in Clinical Applications by Region: (2014) (includes corresponding Graph/Chart)
Table 6. Global Automated and Rapid Microbiological Tests Market in Clinical Applications by Segment: (2014) (includes corresponding Graph/Chart)

Non-Clinical Applications

Table 7. Global Automated and Rapid Microbiological Tests Market in Non-Clinical Applications by Region: (2014) (includes corresponding Graph/Chart)

A Holistic Peek into a Few Noteworthy Trends
The Evolution of Biotechnology – A Crucial Step Ahead in the Growing Popularity of Rapid Microbial Tests
Point-of-Care Rapid Microbiological Testing: Yet to Realize Its Full Potential…

2.COMPETITION

Table 8. Global Microorganism Identification and Resistance Tests Market by Leading Player (2013): Percentage Market Share Breakdown of Value Sales for Becton Dickinson and Co, BioMérieux, and Others (includes corresponding Graph/Chart)
Table 9. Global Blood Screening Market by Leading Player (2013): Percentage Market Share Breakdown of Value Sales for Hologic Gen-Probe, Roche and Others (includes corresponding Graph/Chart)
Table 10. Global GC-CT Testing Market by Leading Player (2013): Percentage Market Share Breakdown of Value Sales for Becton Dickinson & Co, Hologic Gen- Probe, Qiagen NV, Roche and Others (includes corresponding Graph/Chart)

Competitive Dynamics in the C. Difficile Testing Market

Table 11. Global Molecular Diagnostics Market for Clostridium difficile by Leading Player (2013): Percentage Breakdown of Revenues for Becton Dickinson, Cepheid, Meridian and Others (includes corresponding Graph/Chart)
Table 12. Global Immunoassays Market for Clostridium difficile by Leading Player (2013): Percentage Breakdown of Revenues for Meridian and Others (includes corresponding Graph/Chart)

A List of Select Molecular C. difficile Test Products

3.MARKET DRIVERS AND TRENDS

Increasing Incidence of Infectious Diseases – An Opportunity Indicator

Table 13. Reported Cases of Major Infections by Select Geographic Region: 2011

Rising Healthcare Needs of Aging Global Population – A Growth Driver

Table 14. Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
Table 15. Elderly Population (65+ Years) as a % of Total Population (2025) (includes corresponding Graph/Chart)

Rising HIV Prevalance – A Key Opportunity Indicator
Some Significant HIV Statistics by Region: 2011

Table 16. Global Prevalence of HIV Infection in 2012 by Region (in Millions) (includes corresponding Graph/Chart)
Table 17. Newly Infected HIV Population in 2012 by Region (in Millions) (includes corresponding Graph/Chart)
Table 18. Global HIV Related Deaths in 2012 by Region (in Millions) (includes corresponding Graph/Chart)
Table 19. Top Twelve Countries in Apac with The Highest Hiv Incidence (2012) (includes corresponding Graph/Chart)
Table 20. Global HIV Prevalence among Adults and Youth in 2010 (includes corresponding Graph/Chart)

Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease
Ultra-Rapid HIV-Screening Tests put up a Strong Fight against HIV-Epidemic
Accuracy/Reliability of Home HIV Testing: A Bone of Contention
Increase in Healthcare Spending in Emerging Markets to Propel Demand

Table 21. Healthcare Spending as % of GDP in Select Countries (2011) (includes corresponding Graph/Chart)

Rising Emphasis on Lab Automation to Augur Well for Market Growth
Greater Patient Awareness to Drive Growth
Advancements in Molecular Diagnostics - A Boon
Antibiotic Resistant Bacteria Throws the Spotlight on Microbial Testing
Influenza – Boosting Rapid Test Prospects
Select FDA-approved Rapid Detection Tests for Flu A&B: (2012)
Automated Blood Culture Systems: The Gold Standard in the Fight against Bacteremia
Impact of Food Scares on Rapid Microbiological Tests Market
Stringent Norms Necessitate Microbial Food Safety Testing
Rapid Screening Gains Preference over Traditional Food Testing Procedures
Leading Food Processors Resort to Rapid Microbiological Testing
Food Packages of the Future Ingrained with Microbial Alert Systems
Poultry Industry Embraces Rapid Microbiological Testing Technologies
Rapid Microbiological Tests Gain Significance in the Pharma Industry
Key Advantages of Rapid Microbiological Tests for Pharma– In a Nutshell
Growth Direct™ System Creates Waves in the Pharmaceutical Quality Control

4.KEY ISSUES CONFRONTING THE RAPID MICROBIOLOGICAL TESTS MARKET

Validation: An Imperative Prerequisite
Obtaining Regulatory Approval: A Major Non-Technical Hindrance
Non-Conformance to Testing Requirements: A Weighty Concern
Technical and Cost Issues Impede the Uptake of Rapid Microbiological Tests in the Food Sector

5.PRODUCT/TECHNOLOGY OVERVIEW

Automated & Rapid Microbiological Tests: A Definition
How Does a Rapid Test Work?
Enabling Technologies of Automated & Rapid Microbiological Tests
Growth-based Technologies
Viability-based Technologies
Cellular-Component or Artifact-based Technologies
Genomics/Proteomics
Microarrays/Microfluidics
DNA Microchips/Probes
Polymerase Chain Reaction (PCR)
Immunoassay
Nucleic Acid Testing (NAT)
Nucleic Acid Probes
Signal-Amplified Tests
Nucleic Acid Amplification Tests
Traditional Methods with Computer-Aided Imaging
Combination Methods

6.APPLICATION AREAS OF AUTOMATED AND RAPID MICROBIOLOGICAL TESTS – A REVIEW

Clinical Applications
Automated Identification and Susceptibility Systems
Automated Blood Culture Systems
Automated Tuberculosis Systems
Streptococcus Infection Rapid Tests
Streptococcus A Rapid Tests
Streptococcus B Rapid Tests
GC/Chlamydia Rapid Tests
Other Automated & Rapid Microbiological Tests
Respiratory Rapid Tests
RSV/ Influenza Rapid Tests
Gastrointestinal Rapid Tests
Giardia Lamblia Rapid Tests
H. Pylori Rapid Tests
Cryptosporidium Rapid Tests
C. Difficile Rapid Tests
STD Rapid Tests
HIV Rapid Tests
Advantages of Rapid HIV Testing
Disadvantages of Rapid HIV Testing
Syphilis Rapid Tests
Applications in Non-Clinical Investigations
Food/Water Safety Tests
Food Safety Testing: A Lucrative Application Area
qPCR Application in Food Microbiology: Study of Select Micro-Organisms by Target Gene and Food Substrate
Rapid Microbiological Methods in Pharmaceutical Sector
Limitations
Advantages
Applications in Pharmaceutical Sector
Environmental Tests
Other Miscellaneous Applications

7.PRODUCT INNOVATIONS/INTRODUCTIONS

Neogen Rolls Out NeoFilmTM for Microbial Tests
bioMérieux Unveils TEMPO® AC Automated Test
Neogen Introduces New Soleris® Rapid Assays for Sterility Testing
Pall Introduces GeneDisc
Rapid Micro Biosystems to Launch Next-Generation Growth DirectTM Systems
Bruker Unveils Single-Use MALDI BiotargetTM Sample Plates
Becton, Dickinson and Company Introduces BD BACTEC™ SafePod
Applied Visual Sciences Introduces TBDxV™ TB Diagnostic Aid
Neogen Introduces Faster Soleris® Test for Detecting Mold and Yeast
BioControl Systems Develops PCR for Detecting Non-O157 Serotypes of STEC
InDevR Introduces New Virus Counter
MicroPhage Receives Approval from FDA for KeyPath™ MRSA/MSSA Blood Culture Test – BT
Health Canada Approves DuPont’s BAX® System Real-Time Assay
Neogen Receives Approval from AOAC for Reveal 2.0 Test
Life Technologies and University of Pennsylvania School of Veterinary Medicine Introduce TaqMan® Salmonella enteritidis Detection Kit
AdvanDX Obtains 510(k) Clearance from US FDA for GNR Traffic Light™ PNA FISH®
Abbott Laboratories Introduces PLEX-ID™ Biothreat Assay
bioMerieux Receives FDA Clearance for NucliSENS EasyQ MRSA
BD Launches BD Max™ Open System
Luxcel Biosciences and Mocon Develop GreenLight™900 Series
Bruker Launches pTD™ for Homeland Security
Hygiena International Launches EnSURE

8.RECENT INDUSTRY ACTIVITY

MedMira Secures Approval from COFEPRIS
MedMira Secures Marketing Approval for Enriched Version of Reveal® Rapid HIV Test (Europe)
Corgenix Medical Announces Expansion of Viral Hemorrhagic Fever Rapid Testing Facilities in Sierra Leone
MedMira and National Research Council of Canada Ink Collaborative Research Agreement
CML HealthCare Installs BD Kiestra Total Laboratory Automation System at Central Laboratory
BioMérieux Obtains FDA Clearance for Vitek MS Clinical Microbiology System
Cepheid Obtains FDA Clearance for Xpert® MTB/RIF Test
Rapid Micro Biosystems Receives Funding from Various Capital Ventures to Support Growth DirectTM System
Instant BioScan Rolls Out Real-Time Microbial System for Water
Becton, Dickinson and Company Takes Over KIESTRA Lab Automation
Duzen and Bruker Enter into Exclusive Framework Agreement
Bruker Enters into Collaboration with Special Bacteriology Reference Laboratory
Terumo Completes Merger with CaridianBCT
LabCorp to Develop a Novel Laboratory-based Antibiotic Susceptibility Assay
Nanosphere Receives FDA Authorization for Marketing BC-GP Test
BD Diagnostics Introduces New Molecular Test
BD Diagnostics Receives Approval for Plastic Blood Culture Bottles
Cepheid Develops Xpert CT/NG and Xpert CT Next-Generation Molecular Products
BIT Analytical Instruments and DRG Diagnostics Launch New Product for Analyzing Immunoassays Parameters
Verigene System Introduces Instrument for Automatic Bacterial Identification in Blood Culture Test
Block Scientific Supplies BACTECTM 9000 Range of Blood Culture Systems
Valio Signs Agreement with DSM
CML HealthCare Inks Agreement with Becton, Dickinson and Company
Abbott Secures CE Marking for PLEX-IDTM System and Clinical Assays
Abbott Laboratories and Genetics Laboratory to Enter into Collaboration for Development of Molecular Diagnostic Test
Bruker Extends Distribution Agreement with Francisco Soria Melguizo
Laboratory Viollier and Bruker Extend Existing Agreement
Thermo Fisher Scientific Receives FDA Approval for Sensititre OptiRead Automated Fluorometric Plate Reading System
Magellan Biosciences Obtains FDA Approval for Sensititre AIM Automated Inoculation Delivery System
bioMérieux Receives FDA Approval for NucliSENS EasyQ® MRSA
BD Diagnostics Obtains FDA Approval for BD ProbeTecTM Assays
Signature Mapping Medical Sciences Receives Order from Aurum Institute for Health Research
Mindray Medical Takes Over Stake in Hunan Changsha Tiandiren Biotech
UL Acquires MDT and MDRS
Thermo Fisher Scientific Takes over TREK Diagnostic Systems
Eurofins Acquires Lancaster Laboratories
Polyplus-Transfection Inks Agreement with ExcellGene for Transfection Reagents
Merck Acquires Microbiology Division of Biotest
UL Establishes New Water Testing Laboratory in India
Neogen Obtains FDA Clearance Reveal for Salmonella Enteritidis (SE) Fast Test
Sekisui Chemical Acquires Diagnostic Products Business of Genzyme
Dynacare Laboratories Acquires Bruker MALDI Biotyper System
Magellan Biosciences Enters into Partnership with miacom Diagnostics
Lonza Signs Distribution Agreement with Roche
BD Enters into Collaboration with Bruker Daltonics
Seegene Enters into Partnership with Molzym
bioMérieux Enters into Partnership with Shanghai Institutes for Biological Sciences
Becton, Dickinson and Company Acquires Global Rights to Market Micro PRO
Rapid Micro Biosystems Enters Into Partnership with Life Technologies

9.FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (USA)
Abbott Diagnostics (US)
Alere Inc. (US)
Becton Dickinson and Company (US)
bioMerieux SA (France)
bioMerieux, Inc. (USA)
Bio-Rad Laboratories, Inc (US)
Cellabs Pty Ltd (Australia)
Celsis International Plc. (UK)
Coris BioConcept (Belgium)
F. Hoffmann-La Roche Ltd. (Switzerland)
Hologic Gen-Probe Incorporated (US)
MedMira, Inc. (Canada)
Meridian Biosciences, Inc. (US)
Orasure Technologies, Inc. (US)
Orion Diagnostica Oy (Finland)
Quidel Corp. (US)
Sekisui Diagnostics (Japan)
Siemens Healthcare Diagnostics, Inc. (USA)
Thermo Fisher Scientific, Inc. (US)
Oxoid Limited (UK)

10.GLOBAL MARKET PERSPECTIVE

Table 22. World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 23. World Historic Review for Automated and Rapid Microbiological Tests by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 24. World 15-Year Perspective for Automated and Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 25. World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 26. World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 27. World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 28. World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 29. World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 30. World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Percentage Breakdown of Dollar Sales for Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 31. World Recent Past, Current & Future Analysis for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 32. World Historic Review for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 33. World 15-Year Perspective for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 34. World Recent Past, Current & Future Analysis for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 35. World Historic Review for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 36. World 15-Year Perspective for Automated Blood Culture Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 37. World Recent Past, Current & Future Analysis for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 38. World Historic Review for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 39. World 15-Year Perspective for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 40. World Recent Past, Current & Future Analysis for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 41. World Historic Review for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 42. World 15-Year Perspective for Streptococcal Infection Rapid Testsin Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 43. World Recent Past, Current & Future Analysis for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 44. World Historic Review for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 45. World 15-Year Perspective for GC/ Chlamydia Rapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 46. World Recent Past, Current & Future Analysis for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 47. World Historic Review for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 48. World 15-Year Perspective for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 49. World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 50. World Historic Review for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 51. World 15-Year Perspective for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. Market Analysis
Current & Future Analysis
Changing Healthcare Industry Dynamics Affect Rapid and Automated Microbiological Tests Market

Table 52. Healthcare Spending as a % of GDP (includes corresponding Graph/Chart)

Positive Outlook for Rapid and Automated Microbiological Tests Market
Rapidly Ageing Demographics Drive Growth

Table 53. North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)

Competition
Tracking Trends Across Product Segments
Automated Identification & Susceptibility Systems
Growing Popularity of FDA-Approved Automated Susceptibility Testing Equipment
STD Rapid Tests
Market Shares of Leading Players

Table 54. The US Market for Syphilis Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Alere, Becton Dickinson and Others (includes corresponding Graph/Chart)

HIV Rapid Testing Market
Gastrointestinal Rapid Tests

Table 55. The US Market for Rotavirus Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Meridian Biosciences, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart)
Table 56. The US Market for Giardia Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Becton Dickinson, Meridian Biosciences, and Oxoid (includes corresponding Graph/Chart)

Respiratory Rapid Tests
Competition
Market Share Data of Leading Players

Table 57. The US Trichomonas Testing Market by Leading Player (2013): Percentage Breakdown of Revenues for Becton Dickinson and Co, and Hologic GenProbe Inc (includes corresponding Graph/Chart)
Table 58. The US Market for Influenza Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Becton Dickinson, Quidel, Thermo Fisher Scientific and Others (includes corresponding Graph/Chart)
Table 59. The US Market for RSV Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Becton Dickinson, Binax, Thermo Fisher Scientific and Others (includes corresponding Graph/Chart)
Table 60. The US Market for Tuberculosis Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Becton Dickinson and Hologic Gen-Probe (includes corresponding Graph/Chart)
Table 61. The US Market for M. Pneumoniae Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Meridian Biosciences and Oxoid (includes corresponding Graph/Chart)
Table 62. The US Market for Mononucleosis Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Alere, Oxoid, Quidel and Others (includes corresponding Graph/Chart)

Streptococcus Infection Rapid Tests

Table 63. The US Market for Streptococcus A Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Becton Dickinson, Quidel, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart)

Testing Practices of the US Food Industry

Table 64. US Food Safety Testing Market by Contaminant (2013): Percentage Breakdown of Value Sales for Pathogens, GMOs, Toxins, Residues and Others (includes corresponding Graph/Chart)

Increasing Demand for Microbiology Tests in the Food Sector

Table 65. US Microbiological Food Safety Tests by Type (2013): Percentage Share Breakdown in terms of Number of Tests for Routine Tests and Pathogen Tests (includes corresponding Graph/Chart)

Tackling the Burden of Food Borne Illnesses

Table 66. Food-borne Illnesses, Hospitalizations and Deaths in the US (2012): Percentage Share Breakdown for Known Pathogens and Unspecified Agents (includes corresponding Graph/Chart)
Table 67. Leading Pathogens Causing Food- borne Illnesses in the US (2012): Percentage Share Breakdown of Number of Illnesses by Known Pathogens - Norovirus, Salmonella nontyphoidal, Clostridium perfringens, Campylobacter spp., Staphylococcus aureus, and Others (includes corresponding Graph/Chart)
Table 68. Leading Food-borne Pathogens Causing Hospitalizations in the US (2012): Percentage Share Breakdown of Number of Hospitalizations by Known Pathogens - Salmonella nontyphoidal, Norovirus, Campylobacter spp., Toxoplasma gondii, E. coli (STEC) O157, and Others (includes corresponding Graph/Chart)
Table 69. Leading Food-borne Pathogens Causing Deaths in the US (2012): Percentage Share Breakdown of Number of Deaths by Known Pathogens - Salmonella nontyphoidal, Norovirus, Campylobacter spp., Toxoplasma gondii, E. coli (STEC) O157, and Others (includes corresponding Graph/Chart)

Product Launches
Strategic Corporate Developments
Select Key Players
B. Market Analytics

Table 70. The US Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 71. The US Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 72. The US 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

2.CANADA

A. Market Analysis
Current & Future Analysis
Food Safety Testing in Canada

Table 73. Canadian Food-Borne Illnesses by Category (2012): Percentage Share Breakdown of Number of Illness Caused through Known Pathogens and Unknown Pathogens (includes corresponding Graph/Chart)
Table 74. Canadian Food-Borne Illnesses by Pathogen (2012): Percentage Breakdown of number of Illness Caused by Norovirus, Clostridium perfringers, Campylobacter spp, Salmonella spp., non-typhoidal and Others (includes corresponding Graph/Chart)

Strategic Corporate Developments
MedMira, Inc. – A Key Player
B. Market Analytics

Table 75. Canadian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 76. Canadian Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 77. Canadian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

3.JAPAN

A. Market Analysis
Current & Future Analysis
Demographics Drive Market Growth

Table 78. Japanese Population by Age Group (2012) (includes corresponding Graph/Chart)
Table 79. Japanese 65+ Years Population: 1950-2010 (includes corresponding Graph/Chart)

Strategic Corporate Development
Sekisui Diagnostics – A Key Player
B. Market Analytics

Table 80. Japanese Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 81. Japanese Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 82. Japanese 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4.EUROPE

A. Market Analysis
Current & Future Analysis
Debt Crisis in Europe Affects Healthcare Industry
European Healthcare System: In a State of Transition?
Ageing Demography – An Opportunity Indicator

Table 83. Population Breakup by Age Group for Select European Countries: 2011 (as a Percentage of Total Population) (includes corresponding Graph/Chart)

Clinical Vis-à-vis Non-clinical Applications
What Drives the Requirement Patterns of End-Users?
Proliferation of Automated, and Rapid Tests in Clinical Applications
Non-clinical Applications

Table 84. European Microbiological Food Safety Tests (2012): Percentage Share Breakdown of Number of Tests by Segment - Routine Tests and Pathogen Tests (includes corresponding Graph/Chart)

B. Market Analytics

Table 85. European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 86. European Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 87. European 15-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, & Rest of Europe for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 88. European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 89. European Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 90. European 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4A.FRANCE

A. Market Analysis
Current & Future Analysis
Product Launch
Strategic Corporate Development
bioMerieux SA - A Key Player
B. Market Analytics

Table 91. French Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 92. French Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 93. French 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4B.GERMANY

A. Market Analysis
Current & Future Analysis
Food Safety – A Cause of Concern
Food Safety Regulations in Germany
Strategic Corporate Developments
B. Market Analytics

Table 94. German Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 95. German Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 96. German 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4C.ITALY

A. Market Analysis
Current & Future Analysis
B. Market Analytics

Table 97. Italian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 98. Italian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 99. Italian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4D.THE UNITED KINGDOM

A. Market Analysis
Current & Future Analysis
Increasing Incidence of MRSA Spur Growth in Rapid Diagnostics
Non-Clinical Applications to Exhibit Fastest Growth
Key Players
B. Market Analytics

Table 100. The UK Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 101. The UK Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 102. The UK 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4E.SPAIN

A. Market Analysis
Current & Future Analysis
B. Market Analytics

Table 103. Spanish Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 104. Spanish Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 105. Spanish 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4F.RUSSIA

A. Market Analysis
Current & Future Analysis
B. Market Analytics

Table 106. Russian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 107. Russian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 108. Russian 15-Year Perspective for Automated & Rapid Microbiological Tests by End- Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4G.REST OF EUROPE

A. Market Analysis
Current & Future Analysis
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 109. Rest of European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 110. Rest of European Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 111. Rest of European 15-Year Perspective for Automated & Rapid Microbiological Tests by End-use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5.ASIA-PACIFIC

A. Market Analysis
Current & Future Analysis
Healthcare Spending in Asia-Pacific on the Rise
India & China Offer Significant Growth Opportunities

Table 112. China and India Leads Global Population (July 2013): Table Depicting China and India’s Huge Population Vis-a-vis Other Countries’ Population (in Million) by Age Group (includes corresponding Graph/Chart)
Table 113. Age-wise Breakup of China and India’s Population Vis-à-vis Other Populous Countries Globally: As of July 2013 (includes corresponding Graph/Chart)

Asia-Pacific – The Next Epicenter for the AIDS Epidemic
B. Market Analytics

Table 114. Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region – China, India and Rest of Asia-Pacific Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 115. Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - China, India and Rest of Asia-Pacific Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 116. Asia-Pacific 15-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 117. Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 118. Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 119. Asia-Pacific 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5A.CHINA

A. Market Analysis
Current & Future Analysis

Table 120. Leading Players in the Chinese in Vitro Diagnostics Market (2012): Percentage Breakdown of Value Sales for Abbott, Beckman/ Danaher, BioMerieux, DA AN, Hitachi, J&J, Mindray, Roche, Siemens, Symex and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 121. Chinese Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 122. Chinese Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 123. Chinese 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5B.INDIA

A. Market Analysis
Current & Future Analysis
Demand for Automated and Rapid Microbiology Testing Set to Grow in India
Growth Drivers
Automation – Name of the Game
B. Market Analytics

Table 124. Indian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 125. Indian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 126. Indian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5C.REST OF ASIA-PACIFIC

A. Market Analysis
Current & Future Analysis
Cellabs Pty Ltd – A Key Australian Player
B. Market Analytics

Table 127. Rest of Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 128. Rest of Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by End- Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 129. Rest of Asia-Pacific 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

6.LATIN AMERICA

A. Market Analysis
Current & Future Analysis
B. Market Analytics

Table 130. Latin American Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region – Brazil and Rest of Latin America Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 131. Latin American Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - Brazil and Rest of Latin America Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 132. Latin American 15-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin America for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Table 133. Latin American Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 134. Latin American Historic Review for Automated & Rapid Microbiological Tests by End- Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 135. Latin American 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

6A.BRAZIL

A. Market Analysis
Current & Future Analysis
B. Market Analytics

Table 136. Brazilian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 137. Brazilian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 138. Brazilian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

6B.REST OF LATIN AMERICA

A. Market Analysis
Current & Future Analysis
B. Market Analytics

Table 139. Rest of Latin America Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 140. Rest of Latin America Historic Review for Automated & Rapid Microbiological Tests by End- Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 141. Rest of Latin America 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

7.REST OF WORLD

A. Market Analysis
Current & Future Analysis
B. Market Analytics

Table 142. Rest of World Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 143. Rest of World Historic Review for Automated & Rapid Microbiological Tests by End- Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 144. Rest of World 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 103 (including Divisions/Subsidiaries - 115)
The United States (68)
Canada (3)
Japan (5)
Europe (35)
  France (4)
  Germany (10)
  The United Kingdom (7)
  Italy (1)
  Spain (2)
  Rest of Europe (11)
Asia-Pacific (Excluding Japan) (3)
Middle East (1)
Future German Microbiology Testing Market Outlook US$ 4,720.00 Feb, 2012 · 983 pages
Future Italian Microbiology Testing Market Outlook US$ 4,720.00 Feb, 2012 · 970 pages
Future Japanese Microbiology Testing Market Outlook US$ 6,240.00 Feb, 2012 · 976 pages
Future Spanish Microbiology Testing Market Outlook US$ 4,720.00 Feb, 2012 · 960 pages
Future UK Microbiology Testing Market Outlook US$ 4,720.00 Feb, 2012 · 978 pages

Ask Your Question

Automated And Rapid Microbiological Tests: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: